Delcath Reports Strong Growth in Liver Cancer Treatment Sales Amid Rising Costs
Delcath Systems (NASDAQ:DCTH) reported second-quarter revenue of $29.1 million, a significant increase from the previous year's $24.2 million, driven by strong sales growth for its liver cancer treatment HEPZATO KIT and CHEMOSAT in Europe. The company raised its 2026 full-year revenue guidance to between $104 million and $108 million, reflecting continued adoption of the therapy with procedure volume growing roughly 30% year over year. Delcath also reported a gross margin expansion to 90%, indicating improved efficiency in scaling operations. However, rising costs were evident as R&D expenses increased due to expanded clinical trials and SG&A spending grew from $11.4 million to $13.4 million. Despite higher revenue, non-GAAP adjusted EBITDA fell slightly, showing that the company's profitability has not yet kept pace with its growth.
Tickers: $DCTH